13D Filing: Alafi Capital Co LLC and Intra-Cellular Therapies Inc. (ITCI)

---

		SCHEDULE 13D

CUSIP No. 46116X 101				Page 9 of 13 Pages

existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuers business or
corporate structure; (g) changes in the Issuers charter, by-laws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) causing a class of securities of the
Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming
eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (j) any action similar to any of those enumerated above.

Item 5.

Interest in Securities of the Issuer.

(a)-(b):

Number of shares of Common Stock beneficially owned:

Alafi Capital Company, LLC		3,953,270 shares
Christopher Alafi, Ph.D.		5,280,864 shares14
Moshe Alafi		3,953,270 shares15

Percent of class: (The percentage ownership was calculated based on 54,553,353 shares of Common Stock outstanding as of
October 5, 2017).

Alafi Capital Company, LLC			7.2	%
Christopher Alafi, Ph.D.			9.7	%
Moshe Alafi			7.2	%

Number of shares as to which such person has:

(i)	Sole power to vote or to direct the vote:

Alafi Capital Company, LLC		3,953,270 shares
Christopher Alafi, Ph.D.		1,327,594 shares16
Moshe Alafi		0 shares

(ii)	Shared power to vote or to direct the vote:

Alafi Capital Company, LLC		0 shares
Christopher Alafi, Ph.D.		3,953,270 shares17
Moshe Alafi		3,953,270 shares18

(iii)

Sole power to dispose or to direct the disposition of:

Alafi Capital Company, LLC		3,953,270 shares
Christopher Alafi, Ph.D.		1,327,594 shares19
Moshe Alafi		0 shares

14	See Footnotes 2 and 3.

15	See Footnotes 8.

16	See Footnote 2.

17	See Footnote 3.

18	See Footnote 8.

19	See Footnote 4.